2/9
11:32 am
alxo
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
2/5
07:18 am
alxo
ALX Oncology (NASDAQ:ALXO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
ALX Oncology (NASDAQ:ALXO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/31
03:52 pm
alxo
ALX Oncology Announces Pricing of Underwritten Offering [Yahoo! Finance]
Low
Report
ALX Oncology Announces Pricing of Underwritten Offering [Yahoo! Finance]
1/30
08:32 am
alxo
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer [Yahoo! Finance]
Medium
Report
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer [Yahoo! Finance]
1/30
08:30 am
alxo
ALX Oncology Announces Pricing of Underwritten Offering
High
Report
ALX Oncology Announces Pricing of Underwritten Offering
1/30
08:15 am
alxo
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
High
Report
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
1/15
05:21 pm
alxo
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
Low
Report
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference [Yahoo! Finance]
1/12
01:16 pm
alxo
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
Neutral
Report
ALX Oncology Holdings Leads Our Selection Of 3 Promising Penny Stocks [Yahoo! Finance]
1/8
11:00 am
alxo
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/8
08:30 am
alxo
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
Medium
Report
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
12/22
01:07 am
alxo
12/14
01:27 am
alxo
Medium
Report
12/7
08:00 am
alxo
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
Low
Report
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
12/6
01:36 am
alxo
11/18
11:14 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/18
11:00 am
alxo
ALX Oncology to Present at Upcoming Investor Conferences
Medium
Report
ALX Oncology to Present at Upcoming Investor Conferences
11/13
09:53 am
alxo
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
ALX Oncology (NASDAQ:ALXO) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $4.00 price target on the stock.